FIM
RNAC icon

Freedom Investment Management’s Cartesian Therapeutics RNAC Stock Holding History

Freedom Investment Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-708
Closed -$24K – 779
2022
Q4 		$24K Sell
708
-39
-5% -$1.66K ﹤0.01% 699
2022
Q3 		$36.8K Sell
747
-29
-4% -$1.59K ﹤0.01% 710
2022
Q2 		$30.5K Sell
776
-36
-4% -$1.07K ﹤0.01% 716
2022
Q1 		$30K Buy
+812
New +$50.8K ﹤0.01% 764

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Freedom Investment Management's RNAC Position: Q1 2023 in Review

Freedom Investment Management sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 708 shares — an estimated $24K sold.

Freedom Investment Management first reported a position in RNAC in Q1 2022 and held it in 4 quarters. The position peaked at $36.8K in Q3 2022. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • Freedom Investment Management reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Freedom Investment Management sold 708 Cartesian Therapeutics shares in Q1 2023, an estimated $24K.
  • Freedom Investment Management first reported a position in Cartesian Therapeutics in Q1 2022 and held it in 4 quarters.
  • Freedom Investment Management's Cartesian Therapeutics position peaked at $36.8K in Q3 2022.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Freedom Investment Management's 13F filing for Q1 2023, filed 15 May 2023.